KEVIN W.H. YEE, M.D.

Plain English
This study looked at how well patients with acute myeloid leukemia (AML) respond to different treatments, focusing on those who achieve less than complete remission (sub-CR). Out of 363 patients, 227 achieved complete remission while 136 had sub-CR. It was found that patients receiving non-intensive chemotherapy were more likely to have sub-CR responses, and their survival rates were similar to those with complete remission, suggesting that sub-CR does not always mean a worse outcome for these patients. Who this helps: This research benefits AML patients and their doctors by providing insights into treatment responses and survival expectations.

Plain English
This study looked at how death investigators communicate with families after sudden cardiac deaths (SCD) in young people, especially when a hereditary heart condition is suspected. Out of 78 death investigators surveyed, 40% found these cases harder to handle, needing to communicate more often with families, and 96.1% made these contacts by phone. Improving communication is important because it helps families better understand the cause of death and their own risk for similar conditions. Who this helps: This research benefits families affected by sudden cardiac deaths and the professionals responsible for delivering that news.

Plain English
This study looked at how adult patients with a specific type of leukemia, known as Philadelphia-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL), responded to a combination of pediatric-inspired chemotherapy and a medication called a tyrosine kinase inhibitor (TKI). Researchers analyzed data from 141 patients treated over nearly two decades and found that 91.6% of them achieved remission. The most recent treatment approach resulted in a four-year overall survival rate of 87% and a relapse-free survival rate of 69% without needing routine stem cell transplants, which were previously thought to be essential. Who this helps: This benefits adult patients with Ph+ B-ALL and their doctors by offering effective treatment options that may not require stem cell transplants.

Plain English
This study looked at how hoarding symptoms affect college students' social lives and emotional well-being. Researchers found that students with more severe hoarding symptoms experienced less emotional support and companionship, with 37% saying their disorganization was due to a lack of time and 34% citing procrastination as a major issue. Addressing these symptoms early can help improve students' social interactions and overall mental health. Who this helps: This benefits college students struggling with hoarding and their ability to engage socially.

Plain English
This study looked at the effects of a drug called olutasidenib on patients with a type of aggressive leukemia known as acute myeloid leukemia (AML) that arises from a prior blood disorder. The results showed that 40% of the 15 patients achieved complete remission, lasting for an average of about 15.6 months, and 60% experienced some level of response to the treatment. This is significant because it offers new hope for a difficult-to-treat population that has limited options. Who this helps: This helps patients with post-MPN mutated IDH1 acute myeloid leukemia.

Plain English
This study looked at chronic health conditions among transgender and gender diverse (TGD) people who receive Medicare due to disability, focusing on differences based on race, ethnicity, and whether they also receive Medicaid (dual enrollment). The researchers found that TGD individuals on both Medicare and Medicaid had higher rates of chronic conditions—9 out of 10 types of health issues—compared to those on Medicare alone. Specifically, Hispanic TGD beneficiaries were over twice as likely, and Black TGD beneficiaries were over three times as likely, to have infectious diseases compared to White TGD beneficiaries. Who this helps: This research benefits TGD patients and healthcare providers by highlighting disparities that need to be addressed to improve care.

Plain English
This study looked at a combination therapy using olutasidenib and azacitidine for patients with relapsed or refractory acute myeloid leukemia (AML) caused by a specific mutation (mIDH1). Out of 67 patients treated, 31% achieved a complete remission, which lasted for an average of 14.7 months, while over half of the patients showed some level of response. These findings are important as they provide a promising new treatment option for patients with a challenging form of leukemia that does not respond well to standard therapies. Who this helps: This helps patients with relapsed or refractory mIDH1 acute myeloid leukemia.

Plain English
This study looked at how well transgender and gender-diverse individuals in the U.S. who are on Medicare engage with HIV care compared to cisgender individuals from 2008 to 2017. It found that transgender and gender-diverse individuals had a higher likelihood of visiting healthcare providers for HIV care and receiving treatments, with trans feminine individuals being the most engaged. However, there are still significant gaps for transgender men and cisgender women, indicating that more support is needed to ensure everyone can access the necessary HIV care. Who this helps: This benefits patients living with HIV, especially those who are transgender or gender-diverse.

Plain English
This study looked at how often transgender and gender-diverse people on Medicare received gender-affirming surgeries between 2016 and 2020. It found that only 2.1% to 2.2% of these beneficiaries received such surgeries in 2016 and 2017, but this number dropped to 1.4% in 2018 and 2019. The research also showed that younger individuals and those living on the West Coast were more likely to have surgery, highlighting significant regional and demographic differences in access to this essential healthcare. Who this helps: This research benefits transgender and gender-diverse patients seeking gender-affirming surgery.

Plain English
This study looked at how often the central nervous system (CNS) is affected in patients with acute myeloid leukemia (AML) and what factors increase that risk. Out of 259 patients, 31 (about 12%) showed signs of CNS involvement, with high white blood cell counts being a significant risk factor; those with counts over 40 were about 64% likely to be CNS positive. The findings suggest that patients at high risk for CNS involvement should be routinely tested and treated to prevent complications. Who this helps: This benefits patients with AML, particularly those with high white blood cell counts and specific genetic mutations.

Plain English
This study looked at the combination of two drugs, enasidenib and venetoclax, in treating patients with a specific kind of blood cancer called IDH2-mutated acute myeloid leukaemia (AML), who had not responded to previous treatments. They found that 62% of the patients with AML responded to this combination, with half achieving complete remission. Importantly, the treatment was deemed safe, with no unexpected side effects leading to death. Who this helps: This research benefits patients with relapsed or resistant IDH2-mutated AML.

Plain English
This study looked at blood cancers, like leukemia and lymphoma, in adults across Southeast Asia. Researchers found that cancer rates differ a lot between countries; for example, Singapore has the highest rates but also better healthcare, leading to lower death rates. In contrast, countries like Cambodia and Vietnam show lower cancer rates but face challenges in diagnosing and treating these diseases, indicating serious health care inequalities in the region. Who this helps: This benefits patients in Southeast Asia, especially those with blood cancers who may face barriers to effective treatment.

Plain English
In this study, researchers tested a new treatment called RO7283420 in patients with relapsed or hard-to-treat acute myeloid leukemia (AML) to see how safe it is and to determine the best dose. Out of 57 patients receiving the treatment, only 4.8% achieved full remission, and 2.4% had partial recovery of blood cell production. While the treatment showed some ability to activate immune cells, high rates of side effects, particularly cytokine release syndrome (61.3%), led to a conclusion that this method might not be effective enough. Who this helps: This research informs doctors and researchers about the potential and limitations of new treatments for patients with AML.

Plain English
This study looked at how well the Functional Movement Screen (FMS) can predict injuries in first-year cadets at a military college. They found that 90% of female cadets reported pain or injury in just 10 weeks, compared to 48% of male cadets. Even though females scored better on movement and fitness tests, the FMS didn't effectively predict who would get injured, suggesting it may not be useful for the entire military. Who this helps: This research benefits military training programs by highlighting the limitations of current injury screening tools.

Plain English
The study focused on updating the PathBank database, which provides information about metabolic pathways for researchers studying living organisms. The new version, PathBank 2.0, significantly increased the number of key metabolic pathways from 1,720 to 6,951 and the total pathways from 110,234 to 605,359, enhancing the quality of pathway diagrams and descriptions. This matters because it improves researchers' ability to analyze and interpret data related to metabolism and drug interactions, making their work more efficient and effective. Who this helps: This helps researchers and scientists studying metabolism and drug development.

Plain English
This study looked at two treatment approaches for patients with aggressive forms of blood cancers called myeloproliferative neoplasms (MPN) in advanced stages. It found that an intensive treatment approach led to a better overall response rate of 77% compared to 39% for the nonintensive approach. Additionally, the study indicated that certain genetic mutations and poorer health status made treatment responses less effective. Who this helps: This research benefits patients with myeloproliferative neoplasms by identifying effective treatment strategies.

Plain English
This study looked at the effectiveness of guadecitabine compared to various standard treatments in patients with relapsed or refractory acute myeloid leukemia (AML) after intensive chemotherapy. It found that patients taking guadecitabine had a median survival of 6.4 months, while those on standard treatments lived 5.4 months, but this difference was not statistically significant. However, guadecitabine showed higher rates of complete and partial recovery, making it a promising option for certain groups of patients, especially younger ones or those with fewer disease symptoms. Who this helps: This benefits patients with relapsed or refractory AML and their doctors in choosing more effective treatment options.

Plain English
This study looked at the best levels of hemoglobin for giving red blood cell transfusions in adult patients with myelodysplastic syndromes (MDS). It tested two approaches: a liberal approach that aimed to keep hemoglobin levels between 110-120 g/L, and a restrictive approach with a target range of 85-105 g/L. They found that while both methods had some success, the liberal approach led to significantly higher hemoglobin levels and better quality of life scores for patients, even though those patients needed more transfusions. Who this helps: This helps patients with myelodysplastic syndromes and their doctors find better strategies for managing anemia.

Plain English
This study looked at two different methods for continuously monitoring atrial fibrillation (AF), a heart condition, using data from smartwatches. Researchers tested a traditional signal processing method and a more advanced deep learning technique on data from 204 people over four weeks. They found both methods were effective, with the deep learning method analyzing 95% of the data compared to 62% for the traditional method, making it better at handling motion and interruptions. Who this helps: This benefits patients who need reliable heart monitoring, especially those with atrial fibrillation.

Plain English
This study looked at how well transgender and cisgender Medicare recipients engage in HIV care between 2009 and 2017. It found that overall, transgender individuals had a higher likelihood of visiting HIV care providers and receiving treatments compared to their cisgender counterparts. Notably, trans feminine individuals had the best engagement, while trans masculine individuals and cisgender females had the lowest, pointing to significant gaps in care. This matters because understanding these disparities can help improve HIV treatment and support for all groups, ultimately leading to better health outcomes. Who this helps: Patients, especially those living with HIV, and healthcare providers working with diverse populations.

Plain English
This study looked at how an adapted collaborative care model (CoCM) for treating depression worked in a primary care clinic that serves low-income patients. The results showed that 33.3% of patients receiving the new model achieved remission from depression after six months, compared to none in the usual care group. Additionally, 44.4% of those in the adapted model had a significant reduction in their depression symptoms, while only 4.9% of the controls did. This matters because it demonstrates that a modified approach to depression care can lead to better outcomes for patients who might struggle to access traditional treatment. Who this helps: This helps patients in safety-net clinics who are dealing with depression.

Plain English
This study looked at patients with a type of leukemia called acute myeloid leukemia (AML) that is linked to a mutation in a gene called NPM1. Researchers compared outcomes for two groups: those whose AML developed on its own and those whose AML evolved from a previous chronic blood cancer. They found that both groups had similar chances of being free from leukemia after two years (about 52% for the de novo group and 51% for the sAML group) and similar overall survival rates (about 56% for the de novo group and 49% for the sAML group), suggesting that having a prior chronic blood cancer doesn’t significantly affect outcomes for these patients. Who this helps: This helps patients with NPM1-mutated AML, including those with a history of chronic myeloid malignancies.

Plain English
This study focused on how to improve the care for adults with acute leukemia in Ontario, a serious blood cancer that requires complex treatment. Researchers created a list of 229 specific requirements to standardize care, which include things like facility standards, staff training, and patient services. This is important because it aims to ensure that patients receive high-quality, efficient care no matter where they are treated in the province. Who this helps: This benefits patients with acute leukemia and the healthcare providers who care for them.

Plain English
This research looked at how adolescents and young adults (ages 18-39) with acute myeloid leukemia (AML) fare compared to middle-aged patients (ages 40-60). The study found that while overall survival rates were similar for both groups—about 55% for AYA patients and 57% for middle-aged patients—AYA patients who didn't receive a transplant had a higher chance of their cancer returning (nearly 40% compared to 20% for middle-aged patients). These findings highlight the need for tailored treatments for younger patients, especially those not undergoing transplants. Who this helps: This benefits young patients with AML and their doctors by emphasizing the need for more intensive treatments.

Plain English
This study looked at infections in patients with myelodysplastic syndromes (MDS), a type of blood cancer. Out of 1,115 patients, 31% had infections, 19% were hospitalized, and 9% died because of these infections. Those with severe low white blood cell counts or higher-risk MDS faced even more severe outcomes, indicating a strong link between disease severity, treatment type, and infection risks. Who this helps: This research benefits patients with MDS and their doctors by highlighting the risks associated with infections in this population.

Plain English
This study looked at a new treatment called olutasidenib for patients with a specific type of blood cancer, called acute myeloid leukemia (AML), caused by a mutation known as IDH1. Among 153 patients treated, 35% achieved a complete remission, while 48% responded positively to the treatment overall. The responses lasted for an average of nearly 26 months, showing that olutasidenib is effective for this hard-to-treat group of patients. Who this helps: This benefits patients with relapsed or refractory IDH1-mutated AML, offering them a new treatment option.

Plain English
This study looked at adult patients with acute myeloid leukemia (AML) who had inconclusive genetic test results at diagnosis, to see how these results affected their treatment outcomes. Researchers found that 61 patients with inconclusive results had similar survival rates to those with clear results, and many more of them received stem cell transplants (54% compared to 40%). This means that the inconclusive results may not predict poorer outcomes as previously thought, which is important for treatment planning in these patients. Who this helps: This helps patients with AML and their doctors make more informed treatment decisions.

Plain English
This study looked at how frailty impacts hospitalization and healthcare costs for patients with myelodysplastic syndromes (MDS). Among 461 patients, about 81% were hospitalized, spending an average of 10.6 days in the hospital, and the average 30-day care cost was about $8,499. Understanding frailty can help doctors predict healthcare needs and costs for MDS patients, ultimately improving care planning. Who this helps: Patients with MDS and their doctors.

Plain English
This study looked at how effective and cost-efficient it is to target vaccination programs to specific geographic areas that have the highest rates of certain diseases. Researchers reviewed 16 studies and found that focusing resources on these high-burden areas was generally more economical than using a broad, non-targeted approach. For example, in countries with varying levels of disease, targeted programs led to better health outcomes while saving money. Who this helps: This benefits governments and health organizations working to improve vaccination strategies and manage healthcare costs effectively.

Plain English
This study examined how often patients with acute lymphoblastic leukemia (ALL) experience blood clots (venous thromboembolism, or VTE) when treated with two types of asparaginase: pegylated asparaginase (PEG-ASP) and native L-asparaginase (L-ASP). Researchers found that 28.57% of patients on PEG-ASP developed VTE during the initial treatment phase, compared to 10.29% in those on L-ASP, indicating that PEG-ASP is linked to a significantly higher risk of blood clots. This difference continued during later treatment phases, with 34.37% of PEG-ASP patients experiencing VTE versus 13.64% on L-ASP, highlighting the need for better strategies to prevent these complications. Who this helps: This research benefits doctors and healthcare providers managing treatment for adult patients with acute lymphoblastic leukemia.

Plain English
This study looked at the safety of giving the cancer treatment PEG-asparaginase to adults with acute lymphoblastic leukemia who previously experienced dangerously high triglyceride levels. Researchers found that about 67.5% of adult patients treated with PEG-asparaginase developed high triglycerides, which could lead to complications. It’s important to monitor triglyceride levels before and during treatment, but adults can safely receive the drug again once their triglyceride levels return to normal, as long as they didn’t develop serious complications like pancreatitis. Who this helps: This helps adults with acute lymphoblastic leukemia and their doctors.

Plain English
This study investigated a new treatment approach for patients with difficult-to-treat acute myeloid leukemia (AML) by targeting specific enzymes that deactivate cancer drugs. Researchers tested a combination of three drugs, including vismodegib, in patients who had already undergone multiple treatments. They found that vismodegib lowered the level of these deactivating enzymes in the patients' leukemia cells, leading to better responses to the other drugs; in those who showed improvement, there was a noted reduction in enzyme levels. Who this helps: This benefits patients with refractory or relapsed acute myeloid leukemia who have had limited treatment options.

Plain English
This study looked at the health conditions of aging transgender and cisgender individuals enrolled in Medicare from 2008 to 2017. Researchers found that transgender beneficiaries had a higher likelihood of experiencing 25 different health issues compared to cisgender individuals, especially trans feminine individuals who had the highest rates of these conditions. Understanding these health disparities is important for improving healthcare services and support for transgender older adults. Who this helps: This helps transgender patients and the healthcare providers serving them.

Plain English
This study looked at how starting a specific treatment for opioid addiction, buprenorphine/naloxone, in emergency rooms across Alberta could improve care for patients. After implementing the program in 107 emergency departments, more patients received the treatment, with treatment initiation increasing at 11 out of 13 sites. Of the 572 patients referred for follow-up care, 47% went to their first appointment, showing that this program is making it easier for people to get help. Who this helps: This helps patients struggling with opioid addiction by providing immediate treatment and follow-up care.

Plain English
This study looked at how well a new drug called guadecitabine works compared to other standard treatments for patients with newly diagnosed acute myeloid leukemia (AML) who cannot undergo aggressive chemotherapy. The results showed that around 19% of patients on guadecitabine achieved complete remission compared to 17% on standard treatments, and the average survival time was about 7.1 months for guadecitabine and 8.5 months for the other treatments. This matters because it helps doctors decide on treatment options for patients who are not well enough for intensive therapy. Who this helps: This helps patients with acute myeloid leukemia who cannot receive aggressive chemotherapy.

Plain English
This study looked at how living far from a specialized cancer center affected patients with newly diagnosed acute myeloid leukemia (AML) in Ontario, Canada. Researchers analyzed data from 1,310 patients between 2012 and 2017 and found that 29% lived more than 50 kilometers away. Interestingly, the distance did not significantly impact whether patients received intensive chemotherapy or participated in clinical trials, nor did it affect their overall survival rates. Who this helps: This helps patients with AML and their families by showing that distance from treatment centers does not limit their treatment options or outcomes.

Plain English
This study focused on a new method called spray-induced gene silencing (SIGS) to control powdery mildew, a common disease that affects crops like grapes. Researchers found that SIGS can specifically target and silence important genes in the powdery mildew fungus, leading to a significant reduction in disease occurrence across different plant systems. For example, in tests involving six key gene targets, they observed a similar reduction in the fungus, showing that this approach could be effective for various types of powdery mildew. Who this helps: This benefits farmers and agricultural producers by providing a new way to manage powdery mildew in their crops.

Plain English
This study focused on a patient with a rare condition called alloimmune platelet refractoriness, where their body doesn't respond to platelet transfusions due to immune reactions. The research presented the case of a patient with acute myeloid leukemia who experienced dangerous bleeding and showed that plasma exchange—removing and replacing the patient's plasma—could be an effective treatment. This method is not only doable multiple times but can also be tailored to individual needs, making it important for patients with similar immune issues needing help with platelet transfusions. Who this helps: This helps patients with alloimmune platelet refractoriness, particularly those with blood cancers.